This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hernberg-Ståhl, E. Articles by Monson, J. P. Search for Related Content PubMed PubMed Citation Articles by Hernberg-Ståhl, E. Articles by Monson, J. P.

Healthcare Consumption Decreases in Parallel with Improvements in Quality of Life during GH Replacement in Hypopituitary Adults with GH Deficiency

KIGS/KIMS Outcomes Research (E.H.-S., P.W., B.W.), Pharmacia AB, S-11287 Stockholm, Sweden; Department of Medicine III (A.L.), Division of Endocrinology and Metabolism, University of Vienna, 1090 Vienna, Austria; Department of Endocrinology (R.A.), University Hospital, B-2650 Antwerp, Belgium; Research Centre for Endocrinology and Metabolism (B.-Å.B.), Sahlgrenska University Hospital, S-41345 Göteborg, Sweden; Department of Endocrinology (U.F.-R.), Rigshospitalet, DK-2100 Copenhagen, Denmark; and Department of Medicine and Endocrinology (J.P.M.), St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom

Address all correspondence and requests for reprints to: Prof. J. P. Monson, Department of Medicine and Endocrinology, Division of General and Developmental Medicine, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom.

Abstract

The morbidity associated with GH deficiency (GHD) in adults is now well established. Furthermore, many controlled clinical trials have demonstrated the efficacy of GH replacement therapy. The aim of the present study was to determine whether the effects of GH replacement in adults are reflected in a reduced use of healthcare resources, in addition to improving quality of life (QoL). Data concerning visits to the doctor, number of days in hospital, and amount of sick leave were obtained from patients included in KIMS (Pharmacia International Metabolic Database), a large pharmacoepidemiological survey of hypopituitary adults with GHD, for 6 months before GH treatment and for 6–12 months after the start of treatment. Assistance required with normal daily activities was recorded at baseline and after 12 months of GH therapy. QoL (assessed using a disease-specific questionnaire, QoL-Assessment of GHD in Adults) and satisfaction with physical activity during leisure time were also assessed. For the total group (n = 304), visits to the doctor, number of days in hospital, and amount of sick leave decreased significantly (P < 0.05) after 12 months of GH therapy. Patients also needed less assistance with daily activities, although this was significant (P < 0.01) only for the men. QoL improved after 12 months of GH treatment (P < 0.001), and both the amount of physical activity and the patients’ satisfaction with their level of physical activity improved after 12 months (P < 0.001). In conclusion, GH replacement therapy, in previously untreated adults with GHD, produces significant decreases in the use of healthcare resources, which are correlated with improvements in QoL.

This article has been cited by other articles:

				M. Koltowska-Haggstrom, A. F Mattsson, and S. M Shalet Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations Eur. J. Endocrinol., November 1, 2009; 161(S1): S51 - S64. [Abstract] [Full Text] [PDF]

				M Klose, B Jonsson, R Abs, V Popovic, M Koltowska-Haggstrom, B Saller, U Feldt-Rasmussen, and I Kourides From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis Eur. J. Endocrinol., November 1, 2009; 161(S1): S75 - S83. [Abstract] [Full Text] [PDF]

				J. Moock, C. Albrecht, N. Friedrich, H. Volzke, M. Nauck, M. Koltowska-Haggstrom, T. Kohlmann, and H. Wallaschofski Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania Eur. J. Endocrinol., January 1, 2009; 160(1): 17 - 24. [Abstract] [Full Text] [PDF]

				B. Saller, A. F Mattsson, P. H Kann, H. P Koppeschaar, J. Svensson, M. Pompen, and M. Koltowska-Haggstrom Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol., June 1, 2006; 154(6): 843 - 850. [Abstract] [Full Text] [PDF]

				M. Iruthayanathan, Y.-H. Zhou, and G. V. Childs Dehydroepiandrosterone Restoration of Growth Hormone Gene Expression in Aging Female Rats, in Vivo and in Vitro: Evidence for Actions via Estrogen Receptors Endocrinology, December 1, 2005; 146(12): 5176 - 5187. [Abstract] [Full Text] [PDF]

				J. Bollerslev, J. Hallen, K. J Fougner, A. P. Jorgensen, C. Kristo, H. Fagertun, O. Gudmundsen, P. Burman, and T. Schreiner Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial Eur. J. Endocrinol., September 1, 2005; 153(3): 379 - 387. [Abstract] [Full Text] [PDF]

				S. M. Harman and M. R. Blackman Hormones and Supplements: Do They Work?: Use of Growth Hormone for Prevention or Treatment of Effects of Aging J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2004; 59(7): B652 - B658. [Abstract] [Full Text] [PDF]

				J. Svensson and B.-A. Bengtsson Growth Hormone Replacement Therapy and Insulin Sensitivity J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1453 - 1454. [Full Text] [PDF]